Castoldi et al. have reported that 2 weeks administration of EMPA prevented the onset of myocardial hypertrophy and fibrosis in rats with Ang II-induced hypertension by mitigating the cardiac inflammatory response and reducing the expression of tyrosine hydroxylase, a marker of local sympathetic activity [81], and the enzyme catalyzing the first step in the synthesis of catecholamines, the MAO substrates. Here, AGT is linked to cardiac hypertrophy.